Allegis Investment Advisors adds Pfizer (PFE) to its portfolio

Pfizer (PFE) : Allegis Investment Advisors added new position in Pfizer during the most recent quarter end. The investment management firm now holds 33,244 shares of Pfizer which is valued at $1,168,527 , the company said in a statement filed on Aug 8, 2016 with the SEC.Pfizer makes up approximately 0.56% of Allegis Investment Advisors’s portfolio.

Other Hedge Funds, Including , Bailard boosted its stake in PFE in the latest quarter, The investment management firm added 10,791 additional shares and now holds a total of 23,913 shares of Pfizer which is valued at $840,542. Pfizer makes up approx 0.10% of Bailard’s portfolio.Bridgewater Wealth Financial Management reduced its stake in PFE by selling 3,004 shares or 8.39% in the most recent quarter. The Hedge Fund company now holds 32,793 shares of PFE which is valued at $1,157,265. Pfizer makes up approx 0.41% of Bridgewater Wealth Financial Management’s portfolio.Blue Fin Capital reduced its stake in PFE by selling 545 shares or 1.26% in the most recent quarter. The Hedge Fund company now holds 42,622 shares of PFE which is valued at $1,572,326. Pfizer makes up approx 1.27% of Blue Fin Capital’s portfolio.Evergreen Capital Management reduced its stake in PFE by selling 73 shares or 0.2% in the most recent quarter. The Hedge Fund company now holds 36,872 shares of PFE which is valued at $1,358,733. Pfizer makes up approx 0.29% of Evergreen Capital Management’s portfolio. Moon Capital Management added PFE to its portfolio by purchasing 6,737 company shares during the most recent quarter which is valued at $247,113. Pfizer makes up approx 0.30% of Moon Capital Management’s portfolio.

Pfizer opened for trading at $35.05 and hit $35.17 on the upside on Monday, eventually ending the session at $35.11, with a gain of 0.37% or 0.13 points. The heightened volatility saw the trading volume jump to 1,23,54,034 shares. Company has a market cap of $212,965 M.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.